Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer

被引:6
作者
Ahluwalia, MS [1 ]
Daw, HA
机构
[1] Fairview Hosp, Cleveland Clin Hlth Syst, Cleveland, OH 44111 USA
[2] Cleveland Clin Canc Ctr, Cleveland, OH USA
关键词
D O I
10.1200/JCO.2005.03.0213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:7759 / 7760
页数:2
相关论文
共 3 条
[1]   Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J].
Buzdar, AU ;
Ibrahim, NK ;
Francis, D ;
Booser, DJ ;
Thomas, ES ;
Theriault, RL ;
Pusztai, L ;
Green, MC ;
Arun, BK ;
Giordano, SH ;
Cristofanilli, M ;
Frye, DK ;
Smith, TL ;
Hunt, KK ;
Singletary, SE ;
Sahin, AA ;
Ewer, MS ;
Buchholz, TA ;
Berry, D ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3676-3685
[2]  
Buzdar AU, 2003, BREAST CANCER RES TR, V82, pS69
[3]  
WOLFF AC, 2003, P AN M AM SOC CLIN, V22, pA18